Neuroleptics, also called antipsychotic drugs (e.g., haloperidol, risperidone) are the cornerstone drug therapy for psychiatric disorders. Despite the fact that they are widely used in nursing homes, little is known about their clinical determinants. The goal of this cross-sectional study was to determine the prevalence rate of neuroleptic administration and to identify their determinants among 2,332 elderly residents in nursing homes. Among the residents, 649 (27.8%) had taken at least one neuroleptic drug. According to the logistic regression, the factors associated with neuroleptic drug consumption were younger age, few hours of family visits, severe cognitive impairment, insomnia, physical restraint, and disruptive behavior. In conclusion, neuroleptic drugs are administered to more than a quarter of residents in nursing homes. Alternative solutions to sleep problems and disruptive behaviors of the elderly living in long-term-care facilities should be implemented in order to reduce unnecessary use of neuroleptics.
Allard, J., Allaire, D., Leclerc, G., & Langlois, G. S. (1995). The influence of family and social relationships on the consumption of psychotropic drugs by the elderly. Archives of Gerontology and Geriatrics, 20, 193-204.
2.
Auger, L., Durand, P. J., Mercier, P., & Paré, L., (1989). Étude des caractéristiques de la clientèle en liste d’attente pour le réseau institutionnel [Study of the characteristics of patients on a waiting list for institutionalization} (Conseil Régional de la Santé et des Services Sociaux, Région 03). Québec, Canada: Ministère de la Santé et des Services Sociaux.
3.
Beck, C. K., & Shue V. M. (1994). Interventions for treating disruptive behavior in demented elderly people. Nursing Clinics of North America, 29, 143-155.
4.
Beers, M., Avorn, J., Soumerai, S. B., Everitt, D. E., Sherman, D. S., & Salem S. (1988). Psychoactive medication use in intermediate-care facility residents. Journal of the American Medical Association, 26, 3016-3020.
5.
Bélanger, M. (1993). Agitation et atteinte cognitive: Étude transversale en établissement d’hébergement [Agitation and cognitive impairment: A cross-sectional study in long-term care]. Québec, Canada: Université Laval Département de Médecine Sociale et Préventive.
6.
Bernard, S. (1999). Étude descriptive de l’utilisation des contentions physiques auprès des personnes âgées hébergés en centres d’hébergements et de soins de longue durée [Descriptive study on the use of physical restraint among long-term-care residents]. Québec, Canada: Université Laval, Département de Médecine Sociale et Préventive
7.
Besley, D., Kuh, E., & Welsch, R. (1980). Regression diagnostics: Identifying influential data and sources of collinearity. New York: John Wiley.
8.
Board of Directors of the American Geriatric Society [AGS] and American Association for Geriatric Psychiatry. (1997). AGS position statement on psychotherapeutic medications in the nursing home. Retrieved from http://www.americangeriatrics.org/products/positionpapers/psychot.shtml
9.
Bradley, L., & Dfton, B. (1995). Breaking free. Canadian Nurse, 91, 36-40.
10.
Buckwalter, K. C., Stolley, J. M., & Farran, C. J. (1999). Managing cognitive impairment in the elderly: Conceptual, intervention and methodological issues. Online Journal of Knowledge Synthesis for Nursing, 6, 10.
11.
Burke, W. J. (1991). Neuroleptic drug use in the nursing home: The impact of OBRA. American Family Physician, 43(6), 2125-2130.
12.
Carrier L., Arcand, M., & St-Pierre, J. L. (1995). L’usage des neuroleptiques en soins de longue durée[Theuse ofneurolepticsin long-term care]. L’Union médicaledu Canada, pp.35-39.
13.
Castle, N. G. (1999). Changes in resident and facility risk factors for psychotropic drug use in nursing homes since the nursing home reform act. Journal of Applied Gerontology, 18(1), 77-98.
14.
Cohen, D., & Collin, J. (1997). Les toxicomaniesen lien avec les médicaments psychotropes chez les personnes âgées, les femmes et les enfants: Recension et analyse des écrits [Substance dependence associated with psychotropic medications among the elderly, women and children: Review and analysis of the literature]. Québec, Canada: Ministèrede la Santé et des services Sociaux, Groupe de Travail sur la Prévention des Toxicomanie.
15.
Cohen-Mansfield, J., Marx, M. S., & Rosenthal, A. S. (1989). A description of agitation in nursing home. Journal of Gerontology, 44, M77-M84.
16.
Conn, D. K., Furguson, I., Mandelman, K., & Ward, C. (1999). Psychotropic drug utilization in long-term-care facilities for the elderly in Ontario, Canada. International Psychogeriatrics, 11(3), 223-233.
17.
Cooperstock, R. (1971). Sex differences in the use of mood modifying drugs: An explanatory model. Journal of Health and Social Behavior, 12, 228-244.
18.
Cronin-Stubbs, D. (1997). Interventions for cognitive impairment and neurobehavioral disturbances of older adults. Annual Review of Nursing Research, 15, 35-56.
19.
Cummings, J. L. (1995). Dementia: The failing brain. Lancet, 345, 1481-1484.
20.
Dealberto, M. J., Seeman, T., McAvay, G. J., & Berkman, L. (1997). Factors related to current and subsequent psychotropic drug use in an elderly cohort. Journal of Clinical Epidemiology, 50(3), 357-364.
21.
De Leo, D., Stella, A. G., & Spagnoli, A., (1989). Prescription of psychotropic drugs in geriatric institutions. International Journal of Geriatrics Psychiatry, 4, 11-16.
22.
Deslauriers, S., Landreville, P., & Verreault, R. (2001). Validité et fidélité de l’Inventaire d’Agitation de Cohen-Mansfield [Validity and reliability of the Cohen-Mansfield Agitation Inventory]. La Revue Canadienne du Vieillissement, 20(3), 373-384.
23.
Devanand, D. P., Marder, K., Michaels, K. S., Sackeim, H. A., Bell, K., Sullivan, M. A., et al. (1998). A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer’s disease. American Journal of Psychiatry, 155(11), 1512-1520.
24.
Falsetti, A. E. (2000). Risperidone for control of agitation in dementia patients. American Journal of Health-System Pharmacy, 57, 862-870.
25.
Forbes, D. A. (1998). Strategies for managing behavioral symtomatology associated with dementia of the Alzheimer type: A systematic overview. Canadian Journal of Nursing Research, 30, 67-86.
26.
Gerdner, L. A., & Buckwalter, K. C. (1994). A nursing challenge. Assessment and management of agitation in Alzheimer’s patients. Journal of Gerontological Nursing, 20, 11-20.
27.
Gimenez, F., Brazier, M., Calop, J., Dine, T., & Tchiakpé, L. (2000). Pharmacie clinique et thérapeutique [Clinical and therapeutic pharmacology]. Paris: Masson.
28.
Grad, R. M. (1995). Benzodiazepines for insomnia in community-dwelling elderly: A review of benefit and risk. Journal of Family Practice, 41, 473-481.
29.
Grossberg, G. T., & Grossberg, J. A. (1998). Epidemiology of psychotherapeutic drug use in older adults. Clinics in Geriatric Medicine, 14, 1-5.
30.
Gustafsson, T. M., Isacson, D. G. L., Thorslund, M., & Sörbom, D. (1996). Factors associated with psychotropic drug use among the elderly living at home. Journal of Applied Gerontology, 15(2), 238-254.
31.
Hagen. B., & Armstrong-Esther, C. (1999). The question of neuroleptic use in LTC. Canadian Nursing Home, 10, 9-17.
32.
Hall, G. R., & Buckwalter, K. C. (1987). Progressively lowered stress threshold: A conceptual model for care of adults with Alzheimer’s disease. Archives of Psychiatric Nursing, 1(6), 399-406.
33.
Hardin, S. B., Magee, R., Stratmann, D., Vinson, M. H., Owen, M., & Hyatt, E. C. (1994). Extended care and nursing home staff attitudes toward restraints. Moderately positive attitudes exist. Journal of Gerontological Nursing, 20, 23-31.
34.
Helmes, E., Csapo, K. G., & Short, J. A. (1987). Standardization and validation of Multidimensional Observation Scale for Elderly Subjects (MOSES). Journal of Gerontology, 42(4), 395-405.
35.
Hughes, C. M., Lapane, K. L., Mor, V., Ikegami, N., Jonsson, P. V., Ljunggren, G., et al. (2000). The impact of legislation on psychotropic drug use in nursing homes: A cross-national perspective. Journal of the American Geriatrics Society, 48(8), 931-937.
36.
Inouye, S. K. (2000). Prevention of delirium in hospitalized older patients: Risk factors and targeted intervention strategies. Annals in Medicine, 32, 257-263.
37.
Kapur, S., & Seeman, P. (1998). Antipsychotics. In H. Kalant & W. H. E. Roschlau (Eds), Principles of medical pharmacology (pp. 331-344). Oxford, UK: Oxford University Press.
38.
Kirby, M., Denihan, A., Bruce, I., Radic, A., Coakley, D., & Lawlor, B. A. (1999). Benzodiazepineuse among the elderly in the community. International Journal of Geriatric Psychiatry, 14, 280-284.
39.
Koopmans, R. T. C. M., Rossum, J. M., Van den Hoogen, H. J. M., Hekster, Y. A., Willekens-Bogaers, M. A. J. H., & Van Weel, C. (1996). Psychotropic drug use in a group of Dutch nursing home patients with dementia: Many users, long-term use, but low doses. Pharmacy World and Science, 18(1), 42-47.
40.
Lanctôt, K. L., Best, T. S., Mittmann, N., Liu, B., Oh, P. I., Einarson, T. R., et al. (1998). Efficacy and safety of neuroleptics in behavioural disorders associated with dementia. Journal of Clinical Psychiatry, 59, 550-561.
41.
Lanctôt, K. L., Herrmann, N., & Mazzotta, P. (2001). Role of serotonin in the behavioral and psychological symptoms of dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 13(1), 5-21.
42.
Landreville, P., Bordes, M., Dicaire, L., & Verreault, R. (1998). Behavioral approaches for reducing agitation in residents of long-term-care facilities: Critical review and suggestions for future research. International Psychogeriatrics, 10, 397-419.
43.
Larose, D. (1996). Les habitudes de consommation de psychotropes chez les personnes âgées [Patterns of psychotropic drug use among seniors]. Santé Mentale au Québec, 11(1), 291-296.
44.
Lasser, R. A., & Sunderland, T. (1998). Newer psychotropic medication use in nursing home residents. Journal of the American Geriatrics Society, 46(2), 202-207.
45.
Lehne, R. A., Moore, L. A., Crosby, L., & Hamilton, D. B. (2001). Pharmacology for nursing care (4th ed.). Toronto, Canada: W. B. Saunders.
46.
Leroi, I., Steele, C., & Lyketsos, G. (1999). The care of patients with dementia. Reviews in Clinical Gerontology, 9, 235-255.
47.
Lonergan, E., Luxemberg, J., & Colford, J. (2003). Haloperidol for agitation in dementia (Cochrane review). The Cochrane Library, Issue 1. Oxford, UK: Update Software.
48.
Manière, D., D’Athys, P., & Rossignol, S. (1995). Consommation de psychotropes en institution gériatrique [The use of psychotropic drugs in geriatric settings]. La Revue de Gériatrie, 20, 505-512.
49.
McCaillon, P., Toseland, R. W., & Freedman, K. (1999). An evaluation of family visit education program. Journal of the American Geriatrics Society, 47(2), 203-214.
50.
Ministère de la Santé et des Services Sociaux, du Québec. (2001). Le système de santé et de services sociaux au Québec [The Quebec health care and social service system]. Québec, Canada: Gouvernement du Québec.
51.
Mishara, B. L., & McKim, W. A. (1993). Methodological issues in surveying older persons concerning drug use. International Journal of the Addictions, 28, 305-326.
52.
Moisan, J., Chabot, I., & Grégoire, J. P. (2000). L’usage des médicaments psychotropes chez les travailleurs: Prévalence, déterminants et conséquences [The use of psychotropic drugs among workers: Prevalence, determinants and outcomes]. Québec, Canada: Ministère de la Santé et des Services Sociaux. Comité Permanent de Lutte à la Toxicomanie.
53.
Murphy, B. A. (2000). Delirium. Emergency Medicine Clinics of North America, 18(2), 243-252.
54.
Nilsson, K., Palmertierna, T., & Wistedt, B. (1998). Aggressive behaviour in hospitalized psychogeriatric patients. Acta Psychiatrica Scandinavia, 78, 172-175.
55.
Ohayon, J. K., & Caulet, M. (1995). Insomnia and psychotropic drug consumption. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 19, 421-431.
56.
Pelonero, A. L., Levenson, J. L., & Pandurangi, A. K., (1998). Neuroleptic malignant syndrome: A review. Psychiatric Services, 49, 1163-1172.
57.
Pérodeau, G., & Galbaud du Fort, G. (2000). Psychotropic drug use and the relation between social support, life events and mental health in the elderly. Journal of Applied Gerontology, 19(1), 23-41.
58.
Rovner, B. W., Elderman, B. A., Cox, M. P., & Shmuely, Y. (1992). The impact of antipsychotic drug regulation on psychotropic prescribing practices in nursing homes. American Journal of Psychiatry, 149(10), 1390-1392.
59.
Ryden, M. B., Feldt, K. S., Oh, H. L., Brand, K., Warne, M., Weber, E., et al. (1999). Relationships between aggressive behavior in cognitively impaired nursing home residents and use of restraints, psychoactive drugs and secured units. Archives of Psychiatric Nursing, 13(4), 170-178.
60.
Schmidt, I., Claesson, C. B., Westerholm, B., Nilsson, L. G., & Svarstad, B. L. (1998). The impact of regular multidisciplinary team interventions on psychotropic prescribing in Swedish nursing homes. Journal of the American Geriatric Society, 46, 77-82.
61.
Schneider, L. S., Pollock, V. E., & Lyness, S. A. (1990). A meta-analysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatric Society, 38(5), 553-563.
62.
Schorr R., Fought, R. L., & Ray, W. A. (1994). Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87. Regulations. Journal of the American Medical Association, 271(5), 358-362.
63.
Seeman, P. (2002). A typical antipsychotics: Mechanism of action. Canadian Journal of Psychiatry, 47, 27-38.
64.
Skood, I., Nilsson, L., Landahl, S., & Steen, B. (1993). Mental disorders and the use of psychotropic drugs in an 85-year-old urban population. International Psychogeriatrics, 5, 33-48.
65.
Snowdon, L. (1999). Research—A follow-up survey of psychotropic drug use in Sydney nursing homes. Medical Journal of Australia, 170, 299-304.
66.
Sorensen, L., Foldspang, A., Gulmann, N. C., & Munk-Jorgensen, P. (2001). Determinants for the use of psychotropics among nursing home residents. International Journal of Geriatric Psychiatry, 16, 147-154.
67.
Spore, D., Mor, V., Larrat, E. P., Hiris, J., & Hawes, C. (1996). Regulatory environment and psychotropic use in board-and-care facilities: Results of a 10-state study. Journal of Gerontology: Biological Science and Medical, 151, M131-M141.
68.
Strange, P. G. (2001). Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacological Review, 53(1), 119-133.
69.
Sweet, R. A., & Pollock, B. G. (1995). Neuroleptics in the elderly: Guidelines for monitoring. Harvard Review of Psychiatry, 2, 327-335.
70.
Taft, L. B., & Cronin-Stubbs, D. (1995). Behavioral symptoms in dementia: An update. Research in Nursing and Health, 18, 143-163.
71.
Tariot, P. N., Porsteinsson, A., Teri, L., & Weiner, M. F. (1996). Measurement of behavioral disturbance in chronic care populations. Journal of Mental Health and Aging, 2, 213-229.
72.
Thapa, P. B., Meador, K. G., Gideon, P., Fought, R. L., & Ray, W. A. (1994). Effects of antipsychotic withdrawal in elderly nursing home residents. Journal of the American Geriatric Society, 42, 280-286.
73.
World Health Organization Collaborating Center for Drug Statistics Methodology. (2000). Anatomical therapeutic chemical (ATC) classification index. Geneva, Switzerland: World Health Organization.
